doi: 10.1136/bmj.325.7358.269.
Efficacy, safety, and cost of new anticancer drugs
Affiliations
- PMID: 12153927
- PMCID: PMC1123779
- DOI: 10.1136/bmj.325.7358.269
Item in Clipboard
Efficacy, safety, and cost of new anticancer drugs
BMJ.
.
No abstract available
Figures
Comparison of some new drugs with existing drugs
Comment in
-
Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.BMJ. 2002 Nov 30;325(7375):1302; author reply 1302. doi: 10.1136/bmj.325.7375.1302/a. BMJ. 2002. PMID: 12458261 Free PMC article. No abstract available.
-
Efficacy, safety, and cost of new anticancer drugs. Price needs to be evaluated against effectiveness.BMJ. 2002 Nov 30;325(7375):1302; author reply 1302. BMJ. 2002. PMID: 12463189 No abstract available.
Similar articles
-
Oncology drugs enter the US market faster than in Europe but cost more.JAMA. 2012 Aug 8;308(6):555. doi: 10.1001/jama.2012.9535. JAMA. 2012. PMID: 22871850 No abstract available.
-
Approvals in 2016: cost-benefit challenges of new anticancer agents.Nat Rev Clin Oncol. 2017 Feb 20;14(3):133-134. doi: 10.1038/nrclinonc.2017.12. Nat Rev Clin Oncol. 2017. PMID: 28218257 No abstract available.
-
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173. J Natl Cancer Inst. 2017. PMID: 29117395 No abstract available.
-
Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.Cancer Treat Rev. 2017 May;56:1-7. doi: 10.1016/j.ctrv.2017.03.011. Epub 2017 Apr 9. Cancer Treat Rev. 2017. PMID: 28437678 Review.
-
[Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].Lakartidningen. 2009 Jun 3-9;106(23):1563-6. Lakartidningen. 2009. PMID: 19583014 Review. Swedish. No abstract available.
Cited by
-
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.Br J Cancer. 2005 Sep 5;93(5):504-9. doi: 10.1038/sj.bjc.6602750. Br J Cancer. 2005. PMID: 16136026 Free PMC article.
-
Efficacy, safety and cost of new drugs acting on the central nervous system.Eur J Clin Pharmacol. 2003 May;59(1):79-84. doi: 10.1007/s00228-003-0569-3. Epub 2003 Mar 22. Eur J Clin Pharmacol. 2003. PMID: 12743674
-
A new approach to psychiatric drug approval in Europe.PLoS Med. 2013 Oct;10(10):e1001530. doi: 10.1371/journal.pmed.1001530. Epub 2013 Oct 15. PLoS Med. 2013. PMID: 24143137 Free PMC article.
-
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.BMJ. 2017 Oct 4;359:j4530. doi: 10.1136/bmj.j4530. BMJ. 2017. PMID: 28978555 Free PMC article.
-
Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003.Br J Clin Pharmacol. 2005 Apr;59(4):475-8. doi: 10.1111/j.1365-2125.2004.02320.x. Br J Clin Pharmacol. 2005. PMID: 15801943 Free PMC article.
References
-
- Quinn MJ, Babb PJ, Brock A, Kirby EA, Jones J. Cancer trends in England and Wales, 1950-1999. London: Stationery Office; 2001. pp. 206–207. . (Studies on medical and population subjects No 66.)
-
- Levi F, Lucchini F, Negri E, La Vecchia C. The decline in cancer mortality in the European Union, 1988-1996. Eur J Cancer. 2000;36:1965–1968. - PubMed
-
- Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467. - PubMed
-
- Early breast cancer trialists' collaborative group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942. - PubMed
-
- Berrino F, Gatta G, Chessa E, Valente F, Capocaccia R the Eurocare Working Group. Introduction: the Eurocare II study. Eur J Cancer. 1998;34:2139–2153. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
